References
- WilkeTGrothAFuchsAReal life treatment of diabetes mellitus type 2 patients: an analysis based on a large sample of 394,828 German patientsDiabetes Res Clin Pract20141062275 28525176225
- IcksARathmannWHaastertBQuality of care and extent of complications in a population-based sample of patients with type 2 diabetes mellitus. The KORA Survey 2000Dtsch Med Wochenschr200613173 88 German16418944
- OttPBenkeIStelzerJKöhlerCHanefeldMDiabetes in Germany (DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practiceDtsch Med Wochenschr2009134291 297 German19197810
- WrightABurdenACPaiseyRBCullCAHolmanRRUK Prospective Diabetes Study GroupSulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57)Diabetes Care200225330 33611815505
- InzucchiSEBergenstalRMBuseJBManagement of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia2012551577 159622526604
- DavisKLTangiralaMMeyersJLWeiWReal-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapyCurr Med Res Opin2013291083 109123734906
- McAdam-MarxCBouchardJAagrenMNelsonRBrixnerDAnalysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care settingDiabetes Obes Metab20101254 6419758356
- BorahBJDarkowTBouchardJAagrenMFormaFAlemayehuBA comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetesClin Ther200931623 63119393853
- EliassonBEkströmNBruce WirtaSOdénAFardMPSvenssonAMMetabolic effects of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: registry-based observational study in clinical practiceDiabetes Ther20145243 25424828137
- FreemantleNBalkauBHomePDA propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetesDiabetes Obes Metab2013151120 112723782548
- BecherHKostevKSchröder-BernhardiDValidity and representativeness of the Disease Analyzer patient database for use in pharmacoepi-demiological and pharmacoeconomic studiesInt J Clin Pharmacol Ther200947617 62619825325
- MatthaeiSBierwirthRFritscheAGerman Diabetes AssociationMedical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes AssociationExp Clin Endocrinol Diabetes2009117522 55719876795
- SwinnenSGDainMPAronsonRA 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugsDiabetes Care2010331176 117820200301
- HollanderPCooperJBregnhøjJPedersenCBA 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetesClin Ther2008301976 198719108786
- RosenstockJDaviesMHomePDLarsenJKoenenCSchernthanerGA randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetesDiabetologia200851408 41618204830
- LankischMRFerlinzKCLeahyJLScherbaumWAOrals Plus Apidra and Lantus (OPAL) Study GroupIntroducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugsDiabetes Obes Metab2008101178 118519040645
- NilssonPMTheobaldHJournathGFritzTGender differences in risk factor control and treatment profile in diabetes: a study in 229 Swedish primary health care centresScand J Prim Health Care20042227 3115119517
- KooyAde JagerJLehertPLong-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitusArch Intern Med2009169616 62519307526
- DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet20063681696 170517098089